GLI1 upregulates C-JUN through a specific 130-kDa isoform

Area of Science:

• Molecular biology
• Cancer research
• Genetics

Background:

• The Hedgehog signaling pathway plays a role in cancer development and can influence chemotherapy resistance.
• Cisplatin chemotherapy effectiveness is often limited by DNA damage repair mechanisms in cancer cells.
• GLI1 is a key transcription factor in the Hedgehog pathway, regulating gene expression.

Purpose of the Study:

• To investigate the specific role of GLI1 isoforms in the Hedgehog pathway's link to cisplatin resistance.
• To identify which GLI1 isoform is responsible for increased platinum-DNA adduct repair.
• To determine the expression levels of relevant GLI1 isoforms in cancer tissues and cell lines.

Main Methods:

• Utilized Southwestern blot, Electrophoretic Mobility Shift Assay (EMSA), and Chromatin Immunoprecipitation (ChIP) assays.
• Analyzed the expression of different GLI1 isoforms.
• Quantified GLI1 isoform levels in cancerous versus non-malignant tissues and ovarian cancer cell lines.

Main Results:

• One specific 130-kDa isoform of GLI1 was identified as potentially mediating the Hedgehog pathway's connection to C-JUN and platinum-DNA repair.
• This 130-kDa GLI1 isoform was expressed at 6-fold higher levels in cancer tissues compared to non-malignant tissues.
• High abundance of this specific GLI1 isoform was observed in six out of seven examined ovarian cancer cell lines.

Conclusions:

• A specific 130-kDa GLI1 isoform is implicated in enhancing platinum-DNA adduct repair, contributing to cisplatin resistance via the Hedgehog pathway.
• The elevated expression of this GLI1 isoform in ovarian cancers suggests it as a potential therapeutic target for overcoming chemotherapy resistance.